Ondansetron Accord (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Accord, is a serotonin 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent nausea and vomiting associated with chemotherapy, postoperative recovery, and radiation therapy in adult patients. GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 antagonist used in the management of nausea and vomiting pathways triggered by cancer therapies and surgery.

- Chemotherapy‑induced nausea and vomiting: helps prevent acute and delayed episodes in patients receiving cytotoxic drugs. - Postoperative nausea and vomiting: reduces the incidence of nausea after surgical procedures. - Radiation‑induced nausea and vomiting: controls nausea associated with therapeutic radiation exposure.

Side effects reported with ondansetron injectable solutions are generally mild to moderate and vary by individual response.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation. - Severe hypersensitivity: anaphylaxis or angio‑edema. - Serotonin syndrome: agitation, hyperreflexia, fever. - Hepatic dysfunction: elevated liver enzymes. - Severe hypotension: sudden drop in blood pressure. - Neuro‑muscular weakness: rare muscle tone changes.

When using Ondansetron Accord, clinicians should consider several safety aspects before and during therapy.

- Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Electrolyte balance: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before administration. - Concomitant serotonergic drugs: evaluate for serotonin syndrome risk. - Pregnancy and lactation: use only if clearly needed. - Renal or hepatic impairment: adjust monitoring as needed. - Store at 2-8°C: keep refrigerated, protect from light and avoid freezing.

Ondansetron may interact with several drug classes that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Apomatinib?     "); -   \"  ");   " "  " " " " " " " " " " " " " " " " " " " """  "" """ ...

Moderate ");  " " "" "" " " " " " " " " " " " " " " "); " " " " " " " ",